{
  "content": "The Kaplanâ€“Meier estimates of the distribution of times to a recurrence of atrial fibrillation among patients in whom sinus rhythm was restored on day 28 are shown in Figure 2. In subgroups defined according to the duration of atrial fibrillation (one year or less vs. more than one year), the presence or absence of ischemic heart disease, and the presence or absence of symptoms of arrhythmia, amiodarone and sotalol were superior to placebo (Table 2). Amiodarone was superior to sotalol in all subgroups except the subgroup of patients with ischemic heart disease, wherein the time to a recurrence of atrial fibrillation was 569 days in the amiodarone group and 428 days in the sotalol group (P=0.53)",
  "source": "https://www.nejm.org/doi/full/10.1056/NEJMoa041705",
  "chunk_id": "29236e17-74d2-4c31-bf26-0790dff60309",
  "similarity_score": 0.3944631814956665,
  "query": "atrial fibrillation recurrence rates maintenance therapy amiodarone beta-blockers long-term outcomes rhythm maintenance",
  "rank": 17,
  "title": "Amiodarone versus Sotalol for Atrial Fibrillation",
  "authors": "Bramah N. Singh, M.D., D.Sc., Steven N. Singh, M.D., Domenic J. Reda, Ph.D., X. Charlene Tang, M.D., Ph.D., Becky Lopez, R.N., Crystal L. Harris, Pharm.D., Ross D. Fletcher, M.D., Satish C. Sharma, M.D., J. Edwin Atwood, M.D., Alan K. Jacobson, M.D., H. Daniel Lewis, Jr., M.D., Dennis W. Raisch, Ph.D., Michael D. Ezekowitz, M.B., Ch.B., Ph.D.",
  "year": "2005",
  "journal": "New England Journal of Medicine",
  "reference": "Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., Lewis, H. D. Jr., Raisch, D. W., & Ezekowitz, M. D. (2005). Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine, 352(18), 1861-1872. https://doi.org/10.1056/NEJMoa041705",
  "doi": "10.1056/NEJMoa041705",
  "chunk_index": 33,
  "total_chunks": 127,
  "retrieved_at": "2025-07-24T21:58:13.326219"
}